Efficacy and safety of low-intensity pulsed ultrasound (LIPUS) combined with tadalafil in the treatment of severe erectile dysfunction: a retrospective cohort study.

IF 1.9 3区医学 Q4 ANDROLOGY

Translational andrology and urology Pub Date : 2024-09-30 Epub Date: 2024-09-25 DOI:10.21037/tau-24-154

Qing-Qiang Gao, Jing Wang, Da-Sheng Li, Yu-Tian Dai, Zhi-Ran Li, Xiao-Zhi Zhao

{"title":"Efficacy and safety of low-intensity pulsed ultrasound (LIPUS) combined with tadalafil in the treatment of severe erectile dysfunction: a retrospective cohort study.","authors":"Qing-Qiang Gao, Jing Wang, Da-Sheng Li, Yu-Tian Dai, Zhi-Ran Li, Xiao-Zhi Zhao","doi":"10.21037/tau-24-154","DOIUrl":null,"url":null,"abstract":"Background: Low-intensity pulsed ultrasound (LIPUS) is an effective and safe treatment for mild to moderate erectile dysfunction (ED). This study aimed to investigate the efficacy and safety of combining LIPUS with tadalafil in treating severe ED.Methods: The data from 27 patients treated with LIPUS alone (group A) and 21 patients treated with a combination of LIPUS and daily 10 mg tadalafil (group B) were retrospectively analyzed. The LIPUS regimen consisted of twice-weekly treatments for 4 consecutive weeks. The treatment was considered effective if the change in International Index of Erectile Function-Erectile Function Domain (IIEF-EF) score after treatment was greater than or equal to the minimal clinically important difference (MCID) (the MCID for severe ED is 7 points). The effectiveness, IIEF-EF score, erectile hardness score (EHS), peak systolic velocity (PSV), end diastolic velocity (EDV), and adverse events were evaluated before treatment, 4 weeks after treatment, and 12 weeks after treatment.Results: Compared to pre-treatment, both groups showed significant improvement in IIEF-EF score and EHS at 4 and 12 weeks after treatment (P<0.001), with no statistically significant difference between the two time points (P>0.05). The effective rate did not significantly differ between group A (9/27, 33.3%) and group B (10/21, 47.62%) at 4 weeks or between group A (9/27, 33.3%) and group B (12/21, 57.14%) at 12 weeks after treatment (P=0.32, P=0.10). However, in patients without comorbidities, the effective rate of group B (12/18, 66.67%) was higher than that of group A (9/25, 36.00%) at 12 weeks after treatment (P=0.047). After LIPUS treatment, the PSV level significantly increased and the EDV level significantly decreased compared with before treatment (P<0.05). No adverse events were reported.Conclusions: The study suggests that LIPUS has a therapeutic effect on severe ED patients, especially those without comorbidities. It may have a synergistic or overlapping effect with phosphodiesterase type 5 inhibitors (PDE5Is) on severe ED patients without comorbidities.","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 9","pages":"2045-2054"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational andrology and urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tau-24-154","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ANDROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Low-intensity pulsed ultrasound (LIPUS) is an effective and safe treatment for mild to moderate erectile dysfunction (ED). This study aimed to investigate the efficacy and safety of combining LIPUS with tadalafil in treating severe ED.

Methods: The data from 27 patients treated with LIPUS alone (group A) and 21 patients treated with a combination of LIPUS and daily 10 mg tadalafil (group B) were retrospectively analyzed. The LIPUS regimen consisted of twice-weekly treatments for 4 consecutive weeks. The treatment was considered effective if the change in International Index of Erectile Function-Erectile Function Domain (IIEF-EF) score after treatment was greater than or equal to the minimal clinically important difference (MCID) (the MCID for severe ED is 7 points). The effectiveness, IIEF-EF score, erectile hardness score (EHS), peak systolic velocity (PSV), end diastolic velocity (EDV), and adverse events were evaluated before treatment, 4 weeks after treatment, and 12 weeks after treatment.

Results: Compared to pre-treatment, both groups showed significant improvement in IIEF-EF score and EHS at 4 and 12 weeks after treatment (P<0.001), with no statistically significant difference between the two time points (P>0.05). The effective rate did not significantly differ between group A (9/27, 33.3%) and group B (10/21, 47.62%) at 4 weeks or between group A (9/27, 33.3%) and group B (12/21, 57.14%) at 12 weeks after treatment (P=0.32, P=0.10). However, in patients without comorbidities, the effective rate of group B (12/18, 66.67%) was higher than that of group A (9/25, 36.00%) at 12 weeks after treatment (P=0.047). After LIPUS treatment, the PSV level significantly increased and the EDV level significantly decreased compared with before treatment (P<0.05). No adverse events were reported.

Conclusions: The study suggests that LIPUS has a therapeutic effect on severe ED patients, especially those without comorbidities. It may have a synergistic or overlapping effect with phosphodiesterase type 5 inhibitors (PDE5Is) on severe ED patients without comorbidities.

查看原文本刊更多论文

低强度脉冲超声（LIPUS）联合他达拉非治疗严重勃起功能障碍的有效性和安全性：一项回顾性队列研究。

背景：低强度脉冲超声（LIPUS）是治疗轻度至中度勃起功能障碍（ED）的一种有效而安全的方法。本研究旨在探讨 LIPUS 与他达拉非联合治疗重度 ED 的有效性和安全性：回顾性分析了27例单独使用LIPUS治疗的患者（A组）和21例联合使用LIPUS和每日10毫克他达拉非治疗的患者（B组）的数据。LIPUS 治疗方案包括连续 4 周、每周两次的治疗。如果治疗后国际勃起功能指数-勃起功能领域（IIEF-EF）评分的变化大于或等于最小临床重要差异（MCID）（重度ED的MCID为7分），则认为治疗有效。对治疗前、治疗后4周和治疗后12周的疗效、IIEF-EF评分、勃起硬度评分（EHS）、收缩峰值速度（PSV）、舒张末期速度（EDV）和不良反应进行了评估：与治疗前相比，两组患者在治疗后 4 周和 12 周的 IIEF-EF 评分和 EHS 均有显著改善（P0.05）。治疗 4 周后，A 组（9/27，33.3%）和 B 组（10/21，47.62%）的有效率无明显差异，治疗 12 周后，A 组（9/27，33.3%）和 B 组（12/21，57.14%）的有效率也无明显差异（P=0.32，P=0.10）。然而，在无合并症的患者中，B 组（12/18，66.67%）在治疗后 12 周的有效率高于 A 组（9/25，36.00%）（P=0.047）。与治疗前相比，LIPUS 治疗后 PSV 水平明显升高，EDV 水平明显下降（PConclusions：该研究表明，LIPUS 对重度 ED 患者，尤其是无合并症的患者有治疗作用。它与5型磷酸二酯酶抑制剂（PDE5Is）对无合并症的重度ED患者可能具有协同或重叠作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational andrology and urology Medicine-Urology

CiteScore

4.10

自引率

5.00%

发文量

期刊介绍： ranslational Andrology and Urology (Print ISSN 2223-4683; Online ISSN 2223-4691; Transl Androl Urol; TAU) is an open access, peer-reviewed, bi-monthly journal (quarterly published from Mar.2012 - Dec. 2014). The main focus of the journal is to describe new findings in the field of translational research of Andrology and Urology, provides current and practical information on basic research and clinical investigations of Andrology and Urology. Specific areas of interest include, but not limited to, molecular study, pathology, biology and technical advances related to andrology and urology. Topics cover range from evaluation, prevention, diagnosis, therapy, prognosis, rehabilitation and future challenges to urology and andrology. Contributions pertinent to urology and andrology are also included from related fields such as public health, basic sciences, education, sociology, and nursing.